-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 250 billion yuan Chinese patent medicine hospital market is booming again! Recently, the 2022 National Medical Insurance Catalogue was released through the formal review list, and 50 proprietary Chinese medicines were listed, and there were 30 and 15 inside and outside the
list.
Among the 50 proprietary Chinese medicines, there are 45 modern dosage forms, and Chinese medicine injections account for 4; In addition to the acetalone drop pills, 49 proprietary Chinese medicines belong to exclusive varieties; Yangzijiang and Yiling each have 3 varieties selected, Kangyuan, Tasly, Jichuan, Shenwei, Qizheng Tibetan Medicine.
.
.
11 companies each have 2 varieties selected
.
list.
Among the 50 proprietary Chinese medicines, there are 45 modern dosage forms, and Chinese medicine injections account for 4; In addition to the acetalone drop pills, 49 proprietary Chinese medicines belong to exclusive varieties; Yangzijiang and Yiling each have 3 varieties selected, Kangyuan, Tasly, Jichuan, Shenwei, Qizheng Tibetan Medicine.
.
.
11 companies each have 2 varieties selected
.
15 proprietary Chinese medicines hit the 200 billion yuan market, with Ling, Yili, Yangzijiang.
.
.
.
.
Among the 15 proprietary Chinese medicines outside the catalog, except for the 5 production enterprises involved in the Yixin Ketone Drop Pills, the rest of the varieties are exclusive proprietary Chinese medicines
.
From the perspective of dosage forms, 15 proprietary Chinese medicine varieties are mainly modern dosage forms, of which 6 are tablets, 4 capsules and 3 granules; There are only 2 varieties of traditional dosage forms, including Yixinone drops and Lianyu burn cream
.
.
From the perspective of dosage forms, 15 proprietary Chinese medicine varieties are mainly modern dosage forms, of which 6 are tablets, 4 capsules and 3 granules; There are only 2 varieties of traditional dosage forms, including Yixinone drops and Lianyu burn cream
.
2022 medical insurance catalogue adjustment review of proprietary Chinese medicines outside the catalogue
Yiling Pharmaceutical's selected products include anti-depression removal capsules, kidney nourishing heart and tranquility tablets, Yili Pharmaceutical's selected products include Huzhen Qingfeng Capsules and Golden Lotus Effervescent Tablets, and many of the main enterprises of traditional Chinese medicine have products listed, including Tasly's Kunxining granules, Kangyuan Pharmaceutical's Yinqiao Qingqing Heat Tablets, Yangzijiang Pharmaceutical's Lianyu Burn Cream, Jianmin Group's Qirui Stomach Relief Capsules, Fangsheng Pharmaceutical's Xuanqi Jian Bone Tablets, etc
.
.
From the perspective of therapeutic field, 15 proprietary Chinese medicines cover 9 major treatment categories, of which the drugs for respiratory diseases involve 3 varieties, gynecological drugs, drugs for diseases of the musculoskeletal system, drugs for nervous system diseases, drugs for digestive system diseases, etc.
There are 2 varieties each, and there are 1 variety of dermatological drugs, five senses drugs, cardiovascular and cerebrovascular diseases
.
There are 2 varieties each, and there are 1 variety of dermatological drugs, five senses drugs, cardiovascular and cerebrovascular diseases
.
According to Intranet data, the total sales scale of 9 proprietary Chinese medicine treatment categories in 2021 in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) will be close to 200 billion yuan
.
Among them, the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 80 billion yuan, and the sales scale of proprietary Chinese medicines for respiratory diseases, proprietary Chinese medicines for musculoskeletal diseases, proprietary Chinese medicines for digestive diseases, and gynecological proprietary Chinese medicines exceeded 10 billion yuan
.
.
Among them, the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 80 billion yuan, and the sales scale of proprietary Chinese medicines for respiratory diseases, proprietary Chinese medicines for musculoskeletal diseases, proprietary Chinese medicines for digestive diseases, and gynecological proprietary Chinese medicines exceeded 10 billion yuan
.
12 proprietary Chinese medicines were selected through the off-catalog condition 1 (between 2017 and June 30, 2022, new generic drugs approved for listing by the State Food and Drug Administration), of which 9 proprietary Chinese medicines were approved for marketing in 2021, and the lung cleansing and detoxification granules also met the off-list conditions 3 (drugs included in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)"
).
).
In addition, Shixin lozenges and Yixinone drops are off-catalog conditions 2 (drugs with major changes in indications or functional indications between 2017 and June 30, 2022 with the approval of the State Food and Drug Administration); Tang herbal tablets belong to the off-list condition 4, that is, drugs included in the National Essential Medicines
List (2018 Edition).
List (2018 Edition).
As the only non-exclusive proprietary Chinese medicine selected, Yixin Ketone Drops can activate blood stasis, publicize blood veins, and be used for chest paralysis caused by blood stasis, and the manufacturers include Taiji Group, Tianyitang Pharmaceutical, Puhua Pharmaceutical, Huangguo Zhishuang Pharmaceutical, Dongcheng Ocean Pharmaceutical and other 5
.
.
35 exclusive proprietary Chinese medicines have once again broken through, and 5 varieties of more than 1 billion varieties are listed
There are two kinds of drug declaration conditions in this year's medical insurance adjustment catalogue, and condition 1 is the negotiated drug whose agreement expires on December 31, 2022, and the validity period of the agreement includes the validity period of the negotiation agreement and the validity period of the renewal agreement; Condition 2 is the negotiated drugs and other drugs in the list that have undergone major changes in indications or functional indications between 2017 and June 30, 2022 with the approval of the national drug regulatory authorities (including the application for adjustment of the scope of medical insurance payment for renewal drugs in 2022).
Of the 35 proprietary Chinese medicines in the catalogue that passed the formal review, 31 varieties were selected through the catalogue condition 1, and the other 4 varieties were selected through the catalog condition 2, including Shenwei Pharmaceutical's lipid-lowering Tongluo soft capsules, Convert's Pharmaceutical's Converter injection, China-US East China's Bailing capsules, Shaanxi Jianmin Pharmaceutical's Leech Snake Tongluo Capsules, etc
.
.
2022 Medical Insurance Catalogue Adjustment Review Catalogue of Chinese Proprietary Medicine
It is worth mentioning that 35 proprietary Chinese medicines are exclusive varieties, involving 27 enterprises
.
Among them, 8 enterprises such as Yangtze River Pharmaceutical, Jichuan Pharmaceutical, Shenwei Pharmaceutical, Qizheng Tibetan Medicine, Kangchen Pharmaceutical, Changchun High-tech, Shaanxi Jianmin Pharmaceutical, and Changbaishan Pharmaceutical have 2 varieties each
.
.
Among them, 8 enterprises such as Yangtze River Pharmaceutical, Jichuan Pharmaceutical, Shenwei Pharmaceutical, Qizheng Tibetan Medicine, Kangchen Pharmaceutical, Changchun High-tech, Shaanxi Jianmin Pharmaceutical, and Changbaishan Pharmaceutical have 2 varieties each
.
From the perspective of dosage forms, there are 15 capsules in 35 proprietary Chinese medicines, accounting for 42.
86%, 5 granules, 4 injections and oral liquids, and 3 tablets
.
There are only 3 varieties of traditional dosage form products, including Qizheng Tibetan Medicine Safflower Ruyi Pills, Changchun Gaoxin Stomach Cleansing Pain Relief Pills, and Guangyutang Chinese Medicine Pediatric Niu Huang Qingxin San
.
86%, 5 granules, 4 injections and oral liquids, and 3 tablets
.
There are only 3 varieties of traditional dosage form products, including Qizheng Tibetan Medicine Safflower Ruyi Pills, Changchun Gaoxin Stomach Cleansing Pain Relief Pills, and Guangyutang Chinese Medicine Pediatric Niu Huang Qingxin San
.
The four injections selected are Cardioron Injection, Danshen Polyphenolate for Injection, Conlet Injection and Kangai Injection
.
Among them, Danshen polyphenolates for injection, Conlet injection and Kangai injection were once routine catalogue drugs, and after the 2020 edition of the national medical insurance catalogue was announced, it was officially transferred from the conventional catalogue to the medical insurance negotiation catalog
.
.
Among them, Danshen polyphenolates for injection, Conlet injection and Kangai injection were once routine catalogue drugs, and after the 2020 edition of the national medical insurance catalogue was announced, it was officially transferred from the conventional catalogue to the medical insurance negotiation catalog
.
From the perspective of therapeutic fields, 35 proprietary Chinese medicines cover 10 treatment categories
.
Among them, the drugs for digestive system diseases are led by 9 varieties, there are 8 varieties of drugs for cardiovascular and cerebrovascular diseases, 5 varieties of drugs for respiratory diseases and pediatrics, and 2 varieties of drugs for tumor diseases and musculoskeletal diseases
.
.
Among them, the drugs for digestive system diseases are led by 9 varieties, there are 8 varieties of drugs for cardiovascular and cerebrovascular diseases, 5 varieties of drugs for respiratory diseases and pediatrics, and 2 varieties of drugs for tumor diseases and musculoskeletal diseases
.
According to data from the Intranet Network, the total sales scale of 35 proprietary Chinese medicines in China's public medical institutions in 2021 will exceed 9.
3 billion yuan.
Among them, the sales scale of 5 varieties exceeds 1 billion yuan, including green varieties.
Danshen polyphenolate for pharmaceutical injection, Kangai injection of Changbaishan Pharmaceutical, Conlet injection of Convert, Lanqin oral solution of Yangzijiang Pharmaceutical, etc.
; The sales scale of 11 varieties is less than 10 million yuan, and there are 1374 kinds of proprietary drugs in the 2021 edition of the national medical insurance directory, and the enterprise products are not at ease after entering the medical insurance directory, and still face many challenges
.
3 billion yuan.
Among them, the sales scale of 5 varieties exceeds 1 billion yuan, including green varieties.
Danshen polyphenolate for pharmaceutical injection, Kangai injection of Changbaishan Pharmaceutical, Conlet injection of Convert, Lanqin oral solution of Yangzijiang Pharmaceutical, etc.
; The sales scale of 11 varieties is less than 10 million yuan, and there are 1374 kinds of proprietary drugs in the 2021 edition of the national medical insurance directory, and the enterprise products are not at ease after entering the medical insurance directory, and still face many challenges
.
The 250 billion yuan market has risen again, and the entry of proprietary Chinese medicines into medical insurance has accelerated
According to data from the Intranet Network, the sales scale of terminal proprietary Chinese medicines in China's public medical institutions will exceed 250 billion yuan in 2021, an increase of 4.
85%
year-on-year.
The sales scale of proprietary Chinese medicine hospitals in 2018 peaked at more than 280 billion yuan, and then the market continued to be under pressure due to a series of policies such as medical insurance control fees and key monitoring, and the impact of the superimposed epidemic in 2020 fell by 13.
83%, with the gradual elimination of unfavorable factors and the country's vigorous support for the development of the traditional Chinese medicine industry after the epidemic, the market began to pick up, but the collection of proprietary Chinese medicines became a new test
.
85%
year-on-year.
The sales scale of proprietary Chinese medicine hospitals in 2018 peaked at more than 280 billion yuan, and then the market continued to be under pressure due to a series of policies such as medical insurance control fees and key monitoring, and the impact of the superimposed epidemic in 2020 fell by 13.
83%, with the gradual elimination of unfavorable factors and the country's vigorous support for the development of the traditional Chinese medicine industry after the epidemic, the market began to pick up, but the collection of proprietary Chinese medicines became a new test
.
Sales of Terminal Proprietary Chinese Medicines in Public Medical Institutions in China (:100 Million Yuan)
Source: Intranet China's public medical institutions terminal competition pattern
Cardiovascular and cerebrovascular disease drugs are the first drugs in the market of proprietary Chinese medicines, the 2017 edition of the medical insurance catalogue attaches medical insurance restrictions to a number of heavy Chinese medicine injections, and the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases has continued to decline since then, with the first drop of 5.
18% in 2018, a sharp decline of 12.
20% in 2020, and a decline of 1.
64%
in 2021.
With the release of payment restrictions on some Chinese medicine varieties in the medical insurance pilot, the market for proprietary Chinese medicines for cardiovascular and cerebrovascular diseases is expected to stabilize and stop falling
.
18% in 2018, a sharp decline of 12.
20% in 2020, and a decline of 1.
64%
in 2021.
With the release of payment restrictions on some Chinese medicine varieties in the medical insurance pilot, the market for proprietary Chinese medicines for cardiovascular and cerebrovascular diseases is expected to stabilize and stop falling
.
Sales of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases in public medical institutions in China (10,000 yuan)
Source: Intranet China's public medical institutions terminal competition pattern
The medical insurance directory access negotiations have been carried out four times since the establishment of the National Medical Insurance Bureau, and from the perspective of the 50 proprietary Chinese medicines that have passed the formal examination, the number of proprietary Chinese medicines outside the list has increased by 87.
5% compared with 2021, and the number of proprietary Chinese medicines in the directory has increased by 52.
2% compared with 2021, and the pace of proprietary Chinese medicines entering medical insurance has further accelerated
.
5% compared with 2021, and the number of proprietary Chinese medicines in the directory has increased by 52.
2% compared with 2021, and the pace of proprietary Chinese medicines entering medical insurance has further accelerated
.
It is worth noting that the preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug catalogue and the integrity of drug information in that year.
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug catalogue and the integrity of drug information in that year.
According to the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022, the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, and formal review is only one of
them.
, and formal review is only one of
them.
Through the formal review, it is indicated that the drug is eligible for the next step of the expert review process
.
Only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug list
.
Exclusive drugs that pass the review are negotiated, non-exclusive drugs are bidd, and only successful negotiations or bids can be included in the list
.
What is the ultimate fate of the 50 proprietary Chinese medicines, Mi Intranet will continue to pay attention to
.
.
Only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug list
.
Exclusive drugs that pass the review are negotiated, non-exclusive drugs are bidd, and only successful negotiations or bids can be included in the list
.
What is the ultimate fate of the 50 proprietary Chinese medicines, Mi Intranet will continue to pay attention to
.
Source: Intranet database, National Medical Insurance Bureau Note: Intranet "China's public medical institutions terminal competition pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
based on the average retail price of the product at the terminal.
The 250 billion yuan Chinese patent medicine hospital market is booming again! Recently, the 2022 National Medical Insurance Catalogue was released through the formal review list, and 50 proprietary Chinese medicines were listed, and there were 30 and 15 inside and outside the
list.
Among the 50 proprietary Chinese medicines, there are 45 modern dosage forms, and Chinese medicine injections account for 4; In addition to the acetalone drop pills, 49 proprietary Chinese medicines belong to exclusive varieties; Yangzijiang and Yiling each have 3 varieties selected, Kangyuan, Tasly, Jichuan, Shenwei, Qizheng Tibetan Medicine.
.
.
11 companies each have 2 varieties selected
.
list.
Among the 50 proprietary Chinese medicines, there are 45 modern dosage forms, and Chinese medicine injections account for 4; In addition to the acetalone drop pills, 49 proprietary Chinese medicines belong to exclusive varieties; Yangzijiang and Yiling each have 3 varieties selected, Kangyuan, Tasly, Jichuan, Shenwei, Qizheng Tibetan Medicine.
.
.
11 companies each have 2 varieties selected
.
15 proprietary Chinese medicines hit the 200 billion yuan market, with Ling, Yili, Yangzijiang.
.
.
15 proprietary Chinese medicines hit the 200 billion yuan market, with Ling, Yili, Yangzijiang. .
.
.
.
Among the 15 proprietary Chinese medicines outside the catalog, except for the 5 production enterprises involved in the Yixin Ketone Drop Pills, the rest of the varieties are exclusive proprietary Chinese medicines
.
From the perspective of dosage forms, 15 proprietary Chinese medicine varieties are mainly modern dosage forms, of which 6 are tablets, 4 capsules and 3 granules; There are only 2 varieties of traditional dosage forms, including Yixinone drops and Lianyu burn cream
.
Medicines and medicines.
From the perspective of dosage forms, 15 proprietary Chinese medicine varieties are mainly modern dosage forms, of which 6 are tablets, 4 capsules and 3 granules; There are only 2 varieties of traditional dosage forms, including Yixinone drops and Lianyu burn cream
.
2022 medical insurance catalogue adjustment review of proprietary Chinese medicines outside the catalogue
Yiling Pharmaceutical's selected products include anti-depression removal capsules, kidney nourishing heart and tranquility tablets, Yili Pharmaceutical's selected products include Huzhen Qingfeng Capsules and Golden Lotus Effervescent Tablets, and many of the main enterprises of traditional Chinese medicine have products listed, including Tasly's Kunxining granules, Kangyuan Pharmaceutical's Yinqiao Qingqing Heat Tablets, Yangzijiang Pharmaceutical's Lianyu Burn Cream, Jianmin Group's Qirui Stomach Relief Capsules, Fangsheng Pharmaceutical's Xuanqi Jian Bone Tablets, etc
.
.
From the perspective of therapeutic field, 15 proprietary Chinese medicines cover 9 major treatment categories, of which the drugs for respiratory diseases involve 3 varieties, gynecological drugs, drugs for diseases of the musculoskeletal system, drugs for nervous system diseases, drugs for digestive system diseases, etc.
There are 2 varieties each, and there are 1 variety of dermatological drugs, five senses drugs, cardiovascular and cerebrovascular diseases
.
Disease diseaseThere are 2 varieties each, and there are 1 variety of dermatological drugs, five senses drugs, cardiovascular and cerebrovascular diseases
.
According to Intranet data, the total sales scale of 9 proprietary Chinese medicine treatment categories in 2021 in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) will be close to 200 billion yuan
.
Among them, the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 80 billion yuan, and the sales scale of proprietary Chinese medicines for respiratory diseases, proprietary Chinese medicines for musculoskeletal diseases, proprietary Chinese medicines for digestive diseases, and gynecological proprietary Chinese medicines exceeded 10 billion yuan
.
.
Among them, the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 80 billion yuan, and the sales scale of proprietary Chinese medicines for respiratory diseases, proprietary Chinese medicines for musculoskeletal diseases, proprietary Chinese medicines for digestive diseases, and gynecological proprietary Chinese medicines exceeded 10 billion yuan
.
12 proprietary Chinese medicines were selected through the off-catalog condition 1 (between 2017 and June 30, 2022, new generic drugs approved for listing by the State Food and Drug Administration), of which 9 proprietary Chinese medicines were approved for marketing in 2021, and the lung cleansing and detoxification granules also met the off-list conditions 3 (drugs included in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)"
).
).
In addition, Shixin lozenges and Yixinone drops are off-catalog conditions 2 (drugs with major changes in indications or functional indications between 2017 and June 30, 2022 with the approval of the State Food and Drug Administration); Tang herbal tablets belong to the off-list condition 4, that is, drugs included in the National Essential Medicines
List (2018 Edition).
List (2018 Edition).
As the only non-exclusive proprietary Chinese medicine selected, Yixin Ketone Drops can activate blood stasis, publicize blood veins, and be used for chest paralysis caused by blood stasis, and the manufacturers include Taiji Group, Tianyitang Pharmaceutical, Puhua Pharmaceutical, Huangguo Zhishuang Pharmaceutical, Dongcheng Ocean Pharmaceutical and other 5
.
.
35 exclusive proprietary Chinese medicines have once again broken through, and 5 varieties of more than 1 billion varieties are listed
35 exclusive proprietary Chinese medicines have once again broken through, and 5 varieties of more than 1 billion varieties are listed There are two kinds of drug declaration conditions in this year's medical insurance adjustment catalogue, and condition 1 is the negotiated drug whose agreement expires on December 31, 2022, and the validity period of the agreement includes the validity period of the negotiation agreement and the validity period of the renewal agreement; Condition 2 is the negotiated drugs and other drugs in the list that have undergone major changes in indications or functional indications between 2017 and June 30, 2022 with the approval of the national drug regulatory authorities (including the application for adjustment of the scope of medical insurance payment for renewal drugs in 2022).
Of the 35 proprietary Chinese medicines in the catalogue that passed the formal review, 31 varieties were selected through the catalogue condition 1, and the other 4 varieties were selected through the catalog condition 2, including Shenwei Pharmaceutical's lipid-lowering Tongluo soft capsules, Convert's Pharmaceutical's Converter injection, China-US East China's Bailing capsules, Shaanxi Jianmin Pharmaceutical's Leech Snake Tongluo Capsules, etc
.
.
2022 Medical Insurance Catalogue Adjustment Review Catalogue of Chinese Proprietary Medicine
It is worth mentioning that 35 proprietary Chinese medicines are exclusive varieties, involving 27 enterprises
.
Among them, 8 enterprises such as Yangtze River Pharmaceutical, Jichuan Pharmaceutical, Shenwei Pharmaceutical, Qizheng Tibetan Medicine, Kangchen Pharmaceutical, Changchun High-tech, Shaanxi Jianmin Pharmaceutical, and Changbaishan Pharmaceutical have 2 varieties each
.
.
Among them, 8 enterprises such as Yangtze River Pharmaceutical, Jichuan Pharmaceutical, Shenwei Pharmaceutical, Qizheng Tibetan Medicine, Kangchen Pharmaceutical, Changchun High-tech, Shaanxi Jianmin Pharmaceutical, and Changbaishan Pharmaceutical have 2 varieties each
.
From the perspective of dosage forms, there are 15 capsules in 35 proprietary Chinese medicines, accounting for 42.
86%, 5 granules, 4 injections and oral liquids, and 3 tablets
.
There are only 3 varieties of traditional dosage form products, including Qizheng Tibetan Medicine Safflower Ruyi Pills, Changchun Gaoxin Stomach Cleansing Pain Relief Pills, and Guangyutang Chinese Medicine Pediatric Niu Huang Qingxin San
.
86%, 5 granules, 4 injections and oral liquids, and 3 tablets
.
There are only 3 varieties of traditional dosage form products, including Qizheng Tibetan Medicine Safflower Ruyi Pills, Changchun Gaoxin Stomach Cleansing Pain Relief Pills, and Guangyutang Chinese Medicine Pediatric Niu Huang Qingxin San
.
The four injections selected are Cardioron Injection, Danshen Polyphenolate for Injection, Conlet Injection and Kangai Injection
.
Among them, Danshen polyphenolates for injection, Conlet injection and Kangai injection were once routine catalogue drugs, and after the 2020 edition of the national medical insurance catalogue was announced, it was officially transferred from the conventional catalogue to the medical insurance negotiation catalog
.
.
Among them, Danshen polyphenolates for injection, Conlet injection and Kangai injection were once routine catalogue drugs, and after the 2020 edition of the national medical insurance catalogue was announced, it was officially transferred from the conventional catalogue to the medical insurance negotiation catalog
.
From the perspective of therapeutic fields, 35 proprietary Chinese medicines cover 10 treatment categories
.
Among them, the drugs for digestive system diseases are led by 9 varieties, there are 8 varieties of drugs for cardiovascular and cerebrovascular diseases, 5 varieties of drugs for respiratory diseases and pediatrics, and 2 varieties of drugs for tumor diseases and musculoskeletal diseases
.
.
Among them, the drugs for digestive system diseases are led by 9 varieties, there are 8 varieties of drugs for cardiovascular and cerebrovascular diseases, 5 varieties of drugs for respiratory diseases and pediatrics, and 2 varieties of drugs for tumor diseases and musculoskeletal diseases
.
According to data from the Intranet Network, the total sales scale of 35 proprietary Chinese medicines in China's public medical institutions in 2021 will exceed 9.
3 billion yuan.
Among them, the sales scale of 5 varieties exceeds 1 billion yuan, including green varieties.
Danshen polyphenolate for pharmaceutical injection, Kangai injection of Changbaishan Pharmaceutical, Conlet injection of Convert, Lanqin oral solution of Yangzijiang Pharmaceutical, etc.
; The sales scale of 11 varieties is less than 10 million yuan, and there are 1374 kinds of proprietary drugs in the 2021 edition of the national medical insurance directory, and the enterprise products are not at ease after entering the medical insurance directory, and still face many challenges
.
3 billion yuan.
Among them, the sales scale of 5 varieties exceeds 1 billion yuan, including green varieties.
Danshen polyphenolate for pharmaceutical injection, Kangai injection of Changbaishan Pharmaceutical, Conlet injection of Convert, Lanqin oral solution of Yangzijiang Pharmaceutical, etc.
; The sales scale of 11 varieties is less than 10 million yuan, and there are 1374 kinds of proprietary drugs in the 2021 edition of the national medical insurance directory, and the enterprise products are not at ease after entering the medical insurance directory, and still face many challenges
.
The 2500 billion yuan market has risen again, and the entry of proprietary Chinese medicines into medical insurance has accelerated
The 2500 billion yuan market has risen again, and the entry of proprietary Chinese medicines into medical insurance has accelerated According to data from the Intranet Network, the sales scale of terminal proprietary Chinese medicines in China's public medical institutions will exceed 250 billion yuan in 2021, an increase of 4.
85%
year-on-year.
The sales scale of proprietary Chinese medicine hospitals in 2018 peaked at more than 280 billion yuan, and then the market continued to be under pressure due to a series of policies such as medical insurance control fees and key monitoring, and the impact of the superimposed epidemic in 2020 fell by 13.
83%, with the gradual elimination of unfavorable factors and the country's vigorous support for the development of the traditional Chinese medicine industry after the epidemic, the market began to pick up, but the collection of proprietary Chinese medicines became a new test
.
Medicine and medicine85%
year-on-year.
The sales scale of proprietary Chinese medicine hospitals in 2018 peaked at more than 280 billion yuan, and then the market continued to be under pressure due to a series of policies such as medical insurance control fees and key monitoring, and the impact of the superimposed epidemic in 2020 fell by 13.
83%, with the gradual elimination of unfavorable factors and the country's vigorous support for the development of the traditional Chinese medicine industry after the epidemic, the market began to pick up, but the collection of proprietary Chinese medicines became a new test
.
Sales of Terminal Proprietary Chinese Medicines in Public Medical Institutions in China (:100 Million Yuan)
Source: Intranet China's public medical institutions terminal competition pattern
Cardiovascular and cerebrovascular disease drugs are the first drugs in the market of proprietary Chinese medicines, the 2017 edition of the medical insurance catalogue attaches medical insurance restrictions to a number of heavy Chinese medicine injections, and the sales scale of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases has continued to decline since then, with the first drop of 5.
18% in 2018, a sharp decline of 12.
20% in 2020, and a decline of 1.
64%
in 2021.
With the release of payment restrictions on some Chinese medicine varieties in the medical insurance pilot, the market for proprietary Chinese medicines for cardiovascular and cerebrovascular diseases is expected to stabilize and stop falling
.
18% in 2018, a sharp decline of 12.
20% in 2020, and a decline of 1.
64%
in 2021.
With the release of payment restrictions on some Chinese medicine varieties in the medical insurance pilot, the market for proprietary Chinese medicines for cardiovascular and cerebrovascular diseases is expected to stabilize and stop falling
.
Sales of proprietary Chinese medicines for cardiovascular and cerebrovascular diseases in public medical institutions in China (10,000 yuan)
Source: Intranet China's public medical institutions terminal competition pattern
The medical insurance directory access negotiations have been carried out four times since the establishment of the National Medical Insurance Bureau, and from the perspective of the 50 proprietary Chinese medicines that have passed the formal examination, the number of proprietary Chinese medicines outside the list has increased by 87.
5% compared with 2021, and the number of proprietary Chinese medicines in the directory has increased by 52.
2% compared with 2021, and the pace of proprietary Chinese medicines entering medical insurance has further accelerated
.
5% compared with 2021, and the number of proprietary Chinese medicines in the directory has increased by 52.
2% compared with 2021, and the pace of proprietary Chinese medicines entering medical insurance has further accelerated
.
It is worth noting that the preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug catalogue and the integrity of drug information in that year.
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug catalogue and the integrity of drug information in that year.
According to the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022, the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, and formal review is only one of
them.
Enterprise enterprise, and formal review is only one of
them.
Through the formal review, it is indicated that the drug is eligible for the next step of the expert review process
.
Only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug list
.
Exclusive drugs that pass the review are negotiated, non-exclusive drugs are bidd, and only successful negotiations or bids can be included in the list
.
What is the ultimate fate of the 50 proprietary Chinese medicines, Mi Intranet will continue to pay attention to
.
.
Only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug list
.
Exclusive drugs that pass the review are negotiated, non-exclusive drugs are bidd, and only successful negotiations or bids can be included in the list
.
What is the ultimate fate of the 50 proprietary Chinese medicines, Mi Intranet will continue to pay attention to
.
Source: Intranet database, National Medical Insurance Bureau Note: Intranet "China's public medical institutions terminal competition pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Hospital Hospital based on the average retail price of the product at the terminal.
